MAD1L1

Across TCGA pan-cancer cohorts, MAD1L1 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated MAD1L1 data layer compared with 31 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher MAD1L1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MAD1L1 expression acts as an unfavorable survival marker, although some lineages such as COAD show a favorable association.

BRCA, LUAD, and OV are the cancer types where MAD1L1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.462	0.925	<.001	56	view →
LUAD	OS	Median	All	0.175	0.791	<.001	35	view →
OV	DFS	Median	All	0.165	0.541	.004	18	view →
KIRC	OS	Median	All	0.138	0.655	.021	12	view →
ESCA	DFS	Median	II,III,IV	0.190	0.525	.032	9	view →
LIHC	DFS	Median	II,III,IV	0.064	0.417	<.001	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BLCA	DFS	Median	All	0.015	0.594	<.001	6	view →
SARC	OS	Median	All	0.288	0.733	.006	3	view →
COAD	DFS	Median	All	1.000	0.672	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

MAD1L1–BRCA (OS)

Open the BRCA breakdown →